Regulatory PathRegulatory requirements compared

Active substances

Acetylsalicylic acid + Dipyridamole

Open in the medicines table

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
ASPIRIN AND DIPYRIDAMOLE25MG;200MGcapsule, extended release · oralBARRPrescription14 Aug 2009
ASPIRIN AND DIPYRIDAMOLE25MG;200MGcapsule, extended release · oralAMNEAL PHARMSPrescription8 Mar 2016
ASPIRIN AND DIPYRIDAMOLE25MG;200MGcapsule, extended release · oralSANDOZPrescription18 Jan 2017
ASPIRIN AND DIPYRIDAMOLE25MG;200MGcapsule, extended release · oralPH HEALTHPrescription18 Jan 2017
ASPIRIN AND DIPYRIDAMOLE25MG;200MGcapsule, extended release · oralZYDUS PHARMSPrescription29 Aug 2017
ASPIRIN AND DIPYRIDAMOLE25MG;200MGcapsule, extended release · oralDR REDDYSPrescription10 Oct 2018
ASPIRIN AND DIPYRIDAMOLE25MG;200MGcapsule, extended release · oralGLENMARK SPECLTPrescription24 May 2019
ASPIRIN AND DIPYRIDAMOLE25MG;200MGcapsule, extended release · oralMICRO LABSPrescription11 Aug 2021
AGGRENOX25MG;200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**capsule, extended release · oralBOEHRINGER INGELHEIMDiscontinued22 Nov 1999
ASPIRIN AND DIPYRIDAMOLE25MG;200MGcapsule, extended release · oralANI PHARMSDiscontinued18 Jan 2017
ASPIRIN AND DIPYRIDAMOLE25MG;200MGcapsule, extended release · oralSUN PHARMDiscontinued21 Aug 2018
ASPIRIN AND DIPYRIDAMOLE25MG;200MGcapsule, extended release · oralCHARTWELL MOLECULARDiscontinued20 Mar 2019

UK MHRA United Kingdom — marketing authorisations

ProductAuthorisationHolderLegal status
SVELUX 200MG/25MG MODIFIED RELEASE CAPSULES, HARDPL 04416/1362SANDOZ LIMITEDPOM

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.